Cargando…
Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition
Sphingolipids including sphingomyelin have been implicated as potential atherogenic lipids. Studies in apoE (apolipoprotein E)-null mice have revealed that the serine palmitoyltransferase inhibitor myriocin reduces plasma levels of sphingomyelin, ceramide, sphingosine-1-phosphate and glycosphingolip...
Autores principales: | Glaros, Elias N., Kim, Woojin S., Garner, Brett |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860698/ https://www.ncbi.nlm.nih.gov/pubmed/20102334 http://dx.doi.org/10.1042/CS20090452 |
Ejemplares similares
-
SIDT2 Associates with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes
por: Sampieri, Alicia, et al.
Publicado: (2023) -
Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019) -
Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007) -
ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016) -
HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)